Gilead Financial News

19.12 / 04:07

markets Analysis Food Trade hiv Gilead information Lupin shares in focus after FDA approval for generic HIV tablets

Lupin will remain in focus on Thursday after the drugmaker received approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for HIV tablets emtricitabine and tenofovir alafenamide tablets, 200 mg/25 mg. «We wish to confirm that the Company has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Emtricitabine and Tenofovir Alafenamide Tablets, 200 mg/25 mg, to market a generic equivalent of Descovy® Tablets, 200 mg/25 mg of Gilead Sciences, Inc,» Lupin said in an exchange filing.

01.12 / 07:11

hiv Gilead Experts country Latin prevention infection A twice-yearly shot could help end AIDS. But will it get to everyone who needs it?

A twice-yearly shot that prevents HIV infections will be available at low cost in 120 poor countries

01.11 / 17:23

markets Digital Booking Strategy AGN Gilead The Handmaid’s Tale spinoff: Is ‘The Testaments’ finally happening? Here’s what we know

The Testaments in 2022, fans of The Handmaid’s Tale have eagerly awaited more details on the upcoming spinoff. Based on Margaret Atwood’s 2019 sequel to her original 1985 novel, The Testaments explores life in Gilead 15 years after the events that formed the core of The Handmaid’s Tale. Following the narratives of three women, including Aunt Lydia and two young women named Agnes and Daisy, the book explores Gilead’s deep-rooted power dynamics and Aunt Lydia’s evolving stance within the regime. With The Handmaid’s Tale currently in production for its final season, expected to premiere in spring 2025, The Testaments will come to the screen afterward, continuing the universe created by Atwood.

07.09 / 17:28

UPS Moss Gilead Inside actress reports 'The Handmaid’s Tale' Season 6: What to expect and will final chapter be connected to Testaments?

24.07 / 17:46

FIVE Booking Moss Gilead show reports Updates The Handmaid’s Tale Season 6: Expected release window, cast updates and plot

The Handmaid’s Tale have been eagerly awaiting news on the final season of the acclaimed series. With five intense seasons already in the books, viewers are bracing for the concluding chapter of June Osborne's (Elisabeth Moss) harrowing journey in the dystopian world of Gilead. The show, which has garnered both Emmy and Golden Globe awards, is set to wrap up its epic narrative with Season 6, as mentioned in a report by TV Line.

13.02 / 07:09

UPS Aviat Diamondback Trade Gilead reports Trimble, CymaBay Therapy rise; Big Lots, Monday.com fall, Monday, 2/12/2024

Stocks that traded heavily or had substantial price changes on Monday: Trimble, CymaBay Therapy rise; Big Lots, Monday

22.01 / 19:43

Progressive Gilead GILD patient medicines Gilead drops 11% after lung cancer drug trial fails, analysts say stock is 'overreacting'

(Updated — January 22, 2024 12:43 PM EST)

15.01 / 05:47

markets COST hiv Gilead social innovations Courts California Invents a Crazy New Tort

Businesses are often sued for selling allegedly faulty products that aren’t actually defective. Last week a California appeals court ruled that businesses can also be sued for failing to develop a product. Behold California’s new tort standard: You should have built that.

05.01 / 16:51

Moss Gilead Freedom show stage The Handmaid's Tale Season 6: Release date, cast, story & everything we know

The Handmaid's Tale" for its sixth season, the aftermath of the climactic Season 5 finale has left viewers with a multitude of questions and expectations. Here's a comprehensive look at what we know about the upcoming season.

04.01 / 11:59

UPS Merck trends Trade Gilead performer 2024 Eli Lilly stock rally extends as BofA names it top biopharma pick for 2024

Eli Lilly & Co. (NYSE:LLY) added 4.3% Wednesday, marking its strongest performance in two months, following Bank of America's designation of the drugmaker as its top pick among large cap biopharmaceutical companies for 2024.

27.12 / 14:37

FIVE economy Gilead Celebrity Viatris fun 2020 2024 Interest rate cuts will be the story of 2024 — what that means for mortgages and more

The Bank of Canada overnight rate started 2023 at 4.25 per cent and will finish the year at five per cent, for a rise of 0.75 per cent after a rise of four per cent in 2022. I believe we will see a two per cent decline in rates by the end of 2024, back to an overnight rate of three per cent. The impacts of this decline will be the story of 2024.

14.11 / 13:53

FIVE Progressive Entertainment Discover Gilead country innovations 5 Stocks That Raise Dividends Year In, Year Out

The allure of dividends has always been a compelling factor for investors. In this article, we'll take a look at companies that not only offer an attractive dividend yield but also consistently and progressively increase their payouts in recent years.

09.11 / 21:39

Target Progressive CEO Remark Tesla Gilead AbbVie play Stock Market Today: Dow ends lower after Powell signals rate hikes remain in play

Investing.com -- The Dow closed lower Thursday, as Federal Reserve chairman Jerome Powell dealt a blow to bets on sooner rather later rate cuts after signaling that the Fed isn't ready to close the curtain on rate hikes.

08.11 / 01:11

Williams Software Take-Two Gilead reports Dow futures remain steady, eBay, Bumble report earnings

Investing.com — US stock futures were trading higher during Tuesday's evening deals, following a positive session for major benchmark averages as easing yields boosted sentiment, while investors digested a fresh slew of corporate earnings results.

07.11 / 00:19

Williams TripAdvisor Occidental Gilead reports Dow futures trade lower, TripAdvisor lifts 11.9% after earnings

Investing.com — US stock futures were trading lower during Monday's evening deals, following slight gains among major benchmark averages as a fall in bond yields caused investors to reassess market valuations.

14.09 / 07:17

Provident Target Manufacturing Gilead show country valuation stake Cipla founding family’s stake sale in jeopardy over $13 billion valuation target

Cipla Ltd. is in jeopardy as potential buyers have balked at the 1.09 trillion rupee ($13.1 billion) valuation members of the founding family are targeting for the Indian firm in a deal, according to people familiar with the matter. Negotiations between the family members and prospective buyers, including companies in the industry and private equity firms, are no longer moving forward, as the founders are demanding about 1,350 rupees per share, the people said. The price represents a premium of about 10% over Wednesday’s close, according to Bloomberg calculations.

08.09 / 16:09

Target Avid Kroger DocuSign Gilead Solar Stocks making the biggest moves midday: Kroger, DocuSign, Planet Labs, First Solar and more

In this article

08.09 / 12:29

Provident Target Adobe Software Kroger DocuSign Gilead Stocks making the biggest moves before the bell: Kroger, DocuSign, Snowflake, Adobe and more

In this article

21.08 / 18:51

Gilead GILD FDA forces Gilead Sciences to pause enrollment in U.S. leukemia drug trials

Gilead Sciences (NASDAQ:GILD) announced Monday that the U.S. Food and Drug Administration (FDA) had placed a partial clinical hold on the initiation of new patients in U.S. studies evaluating magrolimab to treat acute myeloid leukemia (AML).

28.07 / 15:11

Lowe's Merck Moderna Pfizer CVS Vertex Gilead week Pro Research of the Week: Is Pfizer the Best Bet Among Big Pharma Stocks?

Earnings season is in full swing, and next week, we've got our sights set on the healthcare sector, specifically pharmaceutical and biotechnology companies, as they get ready to reveal their quarterly results.

24.07 / 17:13

BLOCK Entertainment Chevron Intuit Mattel Gilead Warner Bros show Stocks making the biggest moves midday: AMC Entertainment, Mattel, Chevron, Spotify and more

In this article

Gilead Financial News

popular questions about Gilead

What is Gilead and why is it gaining attention?

Where can I find the latest updates on Gilead?

How can I verify the accuracy of information on Gilead?